Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse(R) demonstrates different applications for its use,” Endonovo Therapeutics CEO Alan Collier stated in the news release. “We are quickly becoming the go to pain and edema reduction option for many out-patient surgical procedures performed at ASC’s throughout the US. These centers provide patients with cosmetic and reconstructive procedures resulting in a need for postoperative pain management. Many of the plastic surgery centers have state-of-the-art surgical suites and recovery rooms equipped to hospital standards and we continue working with these centers and completing evaluations. Although in the nascent stages of expanding into fully certified office-based surgery centers, we recognize the large and growing market size allowing us to be well poised to capitalize on this opportunity.”
To view the full press release, visit http://nnw.fm/6ZSp1
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals(R) therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.